Search company, investor...

CorNova

cornova.com

Founded Year

2003

Stage

Unattributed VC | Dead

Total Raised

$2.88M

Last Raised

$380K

About CorNova

The company's FiberHalo stent deployment catheter will enable the physician to deploy the stent and measure in-stent lumen area during the procedure. The FiberHalo post-dilatation catheter will be able to correct for any under-expansion and also measure post-dilatation results. CorNova is developing the Valecor Platinum stent, a bare-metal stent with a pure platinum surface for increased biocompatibility and designed to reduce arterial injury, that has shown performance and anti-restenosis properties compared to current bare-metal stents.

Headquarters Location

21 A Street

Burlington, Massachusetts, 01803,

United States

Missing: CorNova's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CorNova's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

CorNova Patents

CorNova has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/21/2007

8/25/2015

Optical devices, Fluid dynamics, Spectroscopy, Interferometers, Microscopy

Grant

Application Date

12/21/2007

Grant Date

8/25/2015

Title

Related Topics

Optical devices, Fluid dynamics, Spectroscopy, Interferometers, Microscopy

Status

Grant

Latest CorNova News

Global Standard Balloon Catheters Pipeline Report 2022 - Featuring 3DT Holdings, Atrium Medical and CorNova Among Others - ResearchAndMarkets.com

Aug 18, 2022

Standard Balloon Catheters are coronary catheters equipped with a balloon capable of expanding. Scope Extensive coverage of the Standard Balloon Catheters under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Standard Balloon Catheters and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Standard Balloon Catheters under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 3.2 Standard Balloon Catheters - Pipeline Products by Territory 3.3 Standard Balloon Catheters - Pipeline Products by Regulatory Path 3.4 Standard Balloon Catheters - Pipeline Products by Estimated Approval Date 3.5 Standard Balloon Catheters - Ongoing Clinical Trials 4 Standard Balloon Catheters - Pipeline Products under Development by Companies 4.1 Standard Balloon Catheters Companies - Pipeline Products by Stage of Development 4.2 Standard Balloon Catheters - Pipeline Products by Stage of Development 5 Standard Balloon Catheters Companies and Product Overview 5.1 3DT Holdings LLC Company Overview 5.2 Andramed GmbH Company Overview 5.3 Atrium Medical Corp Company Overview 5.4 Cordis Corp Company Overview 5.5 CorNova Inc Company Overview 5.6 Innovia LLC Company Overview 5.7 iVascular SLU Company Overview 5.8 Medix Innovators Inc. Company Overview 5.9 MicroPort Scientific Corp Company Overview 5.10 Natec Medical Ltd Company Overview 5.11 OrbusNeich Company Overview 5.13 SIS Medical AG Company Overview 5.14 Terumo Aortic Company Overview 5.15 Transit Scientific LLC Company Overview 5.16 Vascular Solutions LLC Company Overview 5.17 VasoTech Inc. Company Overview 6 Appendix Source: GlobalData

CorNova Frequently Asked Questions (FAQ)

  • When was CorNova founded?

    CorNova was founded in 2003.

  • Where is CorNova's headquarters?

    CorNova's headquarters is located at 21 A Street, Burlington.

  • What is CorNova's latest funding round?

    CorNova's latest funding round is Unattributed VC.

  • How much did CorNova raise?

    CorNova raised a total of $2.88M.

  • Who are the investors of CorNova?

    Investors of CorNova include AdvanSource Biomaterials Corporation, Secure Point Technologies, CardioTech International and next47.

  • Who are CorNova's competitors?

    Competitors of CorNova include Endologix, Stentys, Avedro, ArraVasc, Micell Technologies and 12 more.

Compare CorNova to Competitors

T
TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

S
SquareOne

SquareOne is developing a stent delivery system.

Tryton Medical Logo
Tryton Medical

Tryton Medical is a developer of stent systems for the treatment of bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using Tri-ZONE technology to offer a dedicated strategy for treating bifurcation lesions. Tryton's cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel. The stent system has received CE Mark and is commercially available throughout Europe, Russia and the Middle East. It is approved in the United States for investigational use only.

S
Svelte Medical Systems

Svelte Medical Systems is engaged in the development of highly deliverable balloon expandable stents. The Svelte IDS is designed to realize the clinical, time and cost-savings benefits of direct stenting in a single platform. Svelte is developing a Sirolimus eluting stent that has non-inflammatory properties, potentially making it less irritating to the vessel lining than stents with typical polymeric coatings. The Svelte DES is being developed to have the same drug release kinetics as the market leaders while potentially minimizing inflammation in the vessel to reduce the need for long term dual anti-platelet therapy.

M
Micell Technologies

Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.